|
| Status |
Public on Nov 10, 2015 |
| Title |
LGWU102540-1036814WU |
| Sample type |
RNA |
| |
|
| Source name |
Breast Tumor CALGB 102540
|
| Organism |
Homo sapiens |
| Characteristics |
gender: female
tissue type: Breast Tumor
fixative: Formalin-Fixed Paraffin Embedded Tissue
|
| Biomaterial provider |
CALGB
|
| Treatment protocol |
The CALGB (Alliance) 9741 adjuvant node-positive breast cancer trial randomized treatment with doxorubicin (A), cyclophosphamide (C), and paclitaxel (T) using a 2x2 factorial design. The two factors were (i) 2-weekly (dose dense; DD) versus 3-weekly administration and (ii) sequential (A→T→C) versus concurrent (AC→T) chemotherapy.
|
| Growth protocol |
N/A
|
| Extracted molecule |
total RNA |
| Extraction protocol |
http://www.nanostring.com/media/pdf/TN_Using_nCounter_with_FFPE_Samples.pdf
|
| Label |
NA
|
| Label protocol |
See manufacturer's website http://www.nanostring.com for procedures
|
| |
|
| Hybridization protocol |
See manufacturer's website http://www.nanostring.com for procedures.
|
| Scan protocol |
See manufacturer's website http://www.nanostring.com for procedures. Digital Analyzer was set to scan at 1155 FOV (fields of view)
|
| Data processing |
See manufacturer's website http://www.nanostring.com. Raw data was background subtracted and normalized to the geometric mean of the housekeepers.
|
| |
|
| Submission date |
Nov 09, 2015 |
| Last update date |
Nov 10, 2015 |
| Contact name |
Sherri R Davies |
| E-mail(s) |
[email protected]
|
| Phone |
3147473073
|
| Organization name |
Washington University
|
| Street address |
4950 Parkview Place
|
| City |
Saint Louis |
| State/province |
MO |
| ZIP/Postal code |
63110 |
| Country |
USA |
| |
|
| Platform ID |
GPL21114 |
| Series (1) |
| GSE74821 |
Gene expression analysis of CALGB 9741 patient tumor samples using the nCounter RUO-PAM50 signature |
|
